体外局部高频热疗联合放疗治疗进展期肝细胞癌患者临床疗效研究

doi:10.3969/j.issn.1672-5069.2021.02.027

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (2): 256-259.doi: 10.3969/j.issn.1672-5069.2021.02.027

体外局部高频热疗联合放疗治疗进展期肝细胞癌患者临床疗效研究

李曼, 李静, 陈文玲, 陈永利, 王力军

054000 河北省邢台市邢台医学高等专科学校第二附属医院放化疗科(李曼,陈文玲,王力军);
普外科(陈永利);
河北医科大学附属第四医院放疗科(李静)

收稿日期:2020-09-29 出版日期:2021-03-10 发布日期:2021-04-30
通讯作者: 王力军,E-mail:lijunwang640915@163.com
作者简介:李曼,女,38岁,医学硕士,主治医师。研究方向:主要从事肿瘤放化疗和热疗治疗研究。E-mail:lm15131381573@163.com
基金资助:
邢台市科技局科研计划项目(编号:2019ZC346)

Clinical observation of external local high frequency thermotherapy and radiotherapy in the treatment of patients with advanced hepatocellular carcinoma

Li Man, Li Jing, Chen Wenling, et al

Department of Radiotherapy and Chemotherapy, Second Affiliated Hospital,Xingtai Medical College, Xingtai 054000,Hebei Province, China

Received:2020-09-29 Online:2021-03-10 Published:2021-04-30

摘要/Abstract

摘要： 目的研究体外局部高频热疗辅助放疗治疗进展期肝细胞癌(HCC)患者的临床疗效。方法采用随机数字表法将66例进展期HCC患者分为对照组33例和观察组33例,分别采取放疗或在放疗的基础上联合体外局部高频热疗治疗,随访12个月。结果观察组客观缓解率(ORR)为 63.6%,显著高于对照组的35.5%(P＜0.05);治疗后,观察组血清甲胎蛋白异质体L3(AFP-L3)水平为(4.2±1.0)ng/ml,高尔基糖蛋白-73(GP73)水平为(55.1±2.6)ng/ml,血管内皮生长因子(VEGF)水平为(200.5±55.7)pg/ml,均显著低于对照组[分别为(5.9±0.9)ng/ml、(62.1±3.5)ng/ml和(265.7±60.3)pg/ml,P＜0.05];观察组放射性肝损伤发生率为21.2%,显著低于对照组的45.2%(P＜0.05);观察组中位总生存时间(OS)为8(95%CI:7～9)个月,1 a累积生存率为14.3%,对照组中位OS为6(95%CI:6～7)个月,1 a累积生存率为11.8%(x²=1.674,P=0.171)。结论采取体外局部高频热疗辅助放疗治疗进展期HCC患者有一定的临床疗效,可使生存获益,并能减轻放射性肝损伤。

关键词: 肝细胞癌, 高频热疗, 放疗, 治疗

Abstract: Objective The aim of this study was to investigate the clinical efficacy of external local high frequency thermotherapy (ELHFT) and radiotherapy in the treatment of patients with advanced hepatocellular carcinoma (HCC).Methods 66 patients with advanced HCC were enrolled in this study, and were randomly divided into control and observation group, with 33 cases in each group. The patients in the control received three-dimensional conformal therapy/intensity modulated radiation therapy (3D-CRT/IMRT), and those in the observation received ELHFT and 3D-CRT/IMRT. All patients were followed-up for 12 months.Results The Objective remission rate in the observation group was 63.6%, significantly higher than 35.5%(P＜0.05) in the control; after treatment, serum alpha-fetoprotein heterogeneity L3 level was (4.2±1.0)ng/ml, Golgi protein-73 level was (55.1±2.6)ng/ml, and vascular endothelial growth factor level was (200.5±55.7)pg/ml, all significantly lower than [(5.9±0.9)ng/ml, (62.1±3.5)ng/ml and (265.7±60.3)pg/ml, respectively, P＜0.05] in the control; the incidence of radiation- induced liver injury in the observation was 21.2%, much lower than 45.2%(P＜0.05) in the control; the median overall survival (OS) in the observation group was 8(95%CI:7-9)m, and the 1-year cumulative survival rate (CSR) was 14.3%, and the median OS in the control was 6(95%CI:6-7)m and the 1-year CSR was 11.8%(x²=1.674,P=0.171).Conclusion The ELHFT and radiotherapy might improve the survival in patients with advanced HCC, which needs further clinical investigation.

Key words: Hepatocellular carcinoma, High frequency thermotherapy, Radiotherapy, Therapy

李曼, 李静, 陈文玲, 陈永利, 王力军. 体外局部高频热疗联合放疗治疗进展期肝细胞癌患者临床疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 256-259.

Li Man, Li Jing, Chen Wenling, et al. Clinical observation of external local high frequency thermotherapy and radiotherapy in the treatment of patients with advanced hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2021, 24(2): 256-259.

参考文献

[1] 程兵, 门伯媛, 徐慧文, 等. 原发性肝癌遗传流行病学研究—遗传因素与遗传模式分析、遗传度计算. 中华肝脏病杂志, 1996, 4(1):36.
[2] Abd-Elsalam S, Elwan N, Soliman H, et al. Epidemiology of liver cancer in Nile delta over a decade: a single-center study. South Asian J Cancer, 2018, 7(1):24-26.
[3] Byun HK, Kim N, Park S, et al. Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma. Strahlenther Onkol, 2019, 195(15):1007-1017.
[4] Lin H, Li X, Liu Y, et al. Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma. ANZ J Surg, 2018, 88(10):e718-e724.
[5] Beste LA, Green PK, Berry K, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol, 2017, 67(1):32-39.
[6] Hamzehalipour J, Nasiri R, Idris A, et al. Trastuzumab-decorated nanoparticles for in vitro and in vivo tumor-targeting hyperthermia of HER2+ breast cancer. J Mater Chem B, 2017, 5(35):7369-7383.
[7] Ba MC, Long H, Wang S, et al. Hyperthermia enhances radiosensitivity of colorectal cancer cells through ROS inducing autophagic cell death. J Cell Biochem, 2018, 119(4):3763-3774.
[8] Yang Y, Yang CL, Zhao ZJ, et al. Microwave hyperthermia enhances the sensitivity of lung cancer cells to gemcitabine through reactive oxygen species-induced autophagic death. Oncol Rep, 2019, 41(5):3100-3110.
[9] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版).中华肝脏病杂志, 2017, 25(12):886-895.
[10] Hamashige S, Arquilla ER. Common terminology criteria for adverse events v3.0 (CTCAE). Principl Pract Clin Trial Med, 2008, 42(4):461-533.
[11] Sargent D, Rubinstein L, Lacombe D, et al. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer, 2009, 45(2):228-247.
[12] European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 2012, 56(4):908-943.
[13] Wang WH,Wang Z, Wu JX, et al. Survival benefit with IMRT following narrow‐margin hepatectomy in patients with hepatocellular carcinoma close to major vessels. Liver Int, 2016, 35(12):2603-2610.
[14] Zhang R, Ma M, Dong G, et al. Increased matrix stiffness promotestumor progression of residual hepatocellular carcinoma after insufficient heat treatment. Cancer Sci, 2017, 108(9):1778-1786.
[15] Ba MC, Long H, Wang S, et al. Hyperthermia enhances radiosensitivity of colorectal cancer cells through ROS inducing autophagic cell death. J Cell Biochem, 2018, 119(4):3763-3774.
[16] Wei T, Zhang W, Tan Q, et al. Electrochemical assay of the alpha fetoprotein-L3 isoform ratio to improve the diagnostic accuracy of hepatocellular carcinoma. Anal Chem, 2018, 90(21):13051-13058.
[17] Lim TS, Kim DY, Han KH ,et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol, 2016, 51(3):344-353.
[18] 王翠晓, 高静. 血清高尔基蛋白73、甲胎蛋白异质体3、甲胎蛋白和α-L-岩藻糖苷酶水平诊断原发性肝癌的效能分析. 实用肝脏病杂志, 2019, 22(1):118-121.
[19] Ismail MM, Morsi HK, Abdulateef NAB, et al. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance. Scand J Clin Lab Inv, 2017, 77(3):175-183.
[20] Zhang W, Ding Y, Zhang C, et al. Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor. Oncogene, 2017,36(27):4277-4287.
[21] Yan F, Li LZ, Lei Z. MicroRNA-26b inhibits the tumor growth of human liver cancer through the PI3K/Akt and NF-κB/MMP-9/VEGF pathways. Oncol Rep, 2018, 39(5):2288-2296.

体外局部高频热疗联合放疗治疗进展期肝细胞癌患者临床疗效研究

Clinical observation of external local high frequency thermotherapy and radiotherapy in the treatment of patients with advanced hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	袁平戈, 陈文雯. 非酒精性脂肪性肝炎新药研发临床思考[J]. 实用肝脏病杂志, 2021, 24(3): 305-307.
[2]	徐文婷, 张继红, 韦冬珏, 李巍. 替诺福韦补救治疗rtM204位点突变的慢性乙型肝炎患者效果研究[J]. 实用肝脏病杂志, 2021, 24(3): 335-338.
[3]	王雪, 瞿发林, 戚伟利, 钱薇. 慢性乙型肝炎患者外周血Treg/Th17比值平衡及其对替比夫定治疗效果的影响[J]. 实用肝脏病杂志, 2021, 24(3): 339-342.
[4]	陈熙, 王玮, 高健伟, 许乐. 合并非酒精性脂肪性肝病对恩替卡韦治疗慢性乙型肝炎患者抗病毒疗效的影响[J]. 实用肝脏病杂志, 2021, 24(3): 343-346.
[5]	裴旭东, 张晓虎, 褚桂克, 李延玲, 赵萍, 王立坤, 陈新菊. 消脂祛浊方治疗合并肥胖的痰湿型非酒精性单纯性脂肪肝患者临床效果初步研究[J]. 实用肝脏病杂志, 2021, 24(3): 355-358.
[6]	齐玫, 张瑞金, 田树萍, 于艳华. 平均血小板体积对自身免疫性肝炎患者治疗不应答的预测价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 371-374.
[7]	王云强, 王丽萍, 黄冬梅, 王艳彬, 刘晓杰, 李明宇, 赵欣宇. 经颈静脉肝内门体静脉分流术治疗乙型肝炎肝硬化门脉高压症患者疗效和血流动力学变化分析[J]. 实用肝脏病杂志, 2021, 24(3): 399-402.
[8]	伍畅, 张远安, 彭春芬. 内镜下套扎术后应用卡维地洛治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(3): 403-406.
[9]	赵凯, 薛晋峰, 薛鹏飞, 常鹏. Viatorr覆膜支架用于TIPS术治疗肝硬化门静脉高压症患者预后研究[J]. 实用肝脏病杂志, 2021, 24(3): 419-422.
[10]	冯浩, 吕海涛, 王子伟, 吴娟. 一步法和分步法治疗胆囊结石合并胆总管结石患者疗效及并发症分析[J]. 实用肝脏病杂志, 2021, 24(3): 435-438.
[11]	朱琳, 秦刚. 妊娠特有肝病诊治进展[J]. 实用肝脏病杂志, 2021, 24(3): 449-452.
[12]	张鑫赫, 田昊宇, 李异玲. 原发性胆汁性胆管炎治疗现状[J]. 实用肝脏病杂志, 2021, 24(3): 453-456.
[13]	郭丽, 宋元宗. Alagille综合征患儿临床治疗管理[J]. 实用肝脏病杂志, 2021, 24(2): 160-163.
[14]	贺宇峰, 钟晓妮, 黄建溶, 赖思奇. 替诺福韦酯与恩替卡韦治疗慢性乙型肝炎患者疗效和血清成纤维细胞生长因子-23水平变化[J]. 实用肝脏病杂志, 2021, 24(2): 200-203.
[15]	聂柳, 彭罕鸣, 廖东亮. 泼尼松和硫唑嘌呤联合熊去氧胆酸治疗自身免疫性肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 224-227.